Medoclazide (Gliclazide)

Gliclazide works by binding to the sulfonylurea receptor (SUR1) on pancreatic β‑cells, which closes ATP‑sensitive potassium channels. This causes cell depolarisation, opens voltage‑dependent calcium channels, and allows calcium influx that triggers insulin granule exocytosis, thereby increasing circulating insulin and reducing plasma glucose.

The appropriate dose of Medoclazide is determined individually by a qualified healthcare professional based on the patient’s glycaemic status, renal function, and concomitant therapies. The prescriber will select the starting dose and any subsequent adjustments to achieve optimal blood‑glucose control while minimising the risk of hypoglycaemia.

Gliclazide is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate well‑controlled studies in pregnant women. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and always under medical supervision.

To place an order, submit an enquiry on the Medoclazide product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with first‑generation sulfonylureas, gliclazide has a longer half‑life, a lower risk of severe hypoglycaemia and a more favourable safety profile. Within the second‑generation class, it is often preferred for its once‑daily dosing and its demonstrated cardiovascular safety in clinical studies, although individual response may vary.

Medoclazide should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not store in the bathroom or near heat sources.

Medoclazide is taken orally, usually once daily with the first main meal of the day to reduce the risk of hypoglycaemia. The tablet should be swallowed whole with a glass of water and not chewed or crushed. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as skin rash, angioedema or anaphylaxis. Hematologic abnormalities like agranulocytosis and hepatic dysfunction have also been reported. Prompt medical attention is required if any of these events occur.

Medoclazide is contraindicated in patients with known hypersensitivity to gliclazide or other sulfonylureas, in individuals with severe renal or hepatic impairment, and in patients with diabetic ketoacidosis. It should also be avoided in those with a history of severe hypoglycaemic episodes unless closely monitored by a physician.